Eli Lilly News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Orderbuch			Analysen
Historisch

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Orderbuch

Analysen

Historisch

31.01.17	Jaguar Animal Health Signs With Elanco Global To Co-Promote Canalevia (RTTNews)
30.01.17	Lilly Revises Time for Conference Call for Fourth-Quarter 2016 Financial Results Announcement (PR Newswire)
27.01.17	Eli Lilly Ends Collaboration Agreement On Adocia's Lispro Insulin - Quick Facts (RTTNews)
24.01.17	Galliprant® (grapiprant tablets) Now Available for Canine Osteoarthritis (PR Newswire)
23.01.17	Inovalon Announces Deal With Boehringer Ingelheim (RTTNews)
19.01.17	DERM Delights With A Hat-trick, Shot In The Arm For APRI, FDA Nod For TEVA (RTTNews)
18.01.17	Eli Lilly To Buy CoLucid Pharma In $960 Mln Deal - Quick Facts (RTTNews)
18.01.17	Lilly and CoLucid Pharmaceuticals Announce Agreement for Lilly To Acquire CoLucid (PR Newswire)
17.01.17	FDA Delays Decision On Lilly's Rheumatoid Arthritis Drug Candidate (RTTNews)
13.01.17	U.S. FDA Extends Review Period for Baricitinib, an Investigational Rheumatoid Arthritis Treatment (PR Newswire)
13.01.17	Teva Loses Alimta Appeal Against Eli Lilly (RTTNews)
12.01.17	U.S. Court of Appeals Rules In Lilly's Favor On Alimta Vitamin Regimen Patent (PR Newswire)
11.01.17	Lilly, Merck Expand Immuno-Oncology Collaboration (RTTNews)
11.01.17	Lilly and Merck Expand Immuno-Oncology Collaboration (PR Newswire)
05.01.17	Lilly Confirms Date and Conference Call for Fourth-Quarter 2016 Financial Results Announcement (PR Newswire)
05.01.17	Lilly Announces Changes In Organization, Leadership Structure - Quick Facts (RTTNews)
05.01.17	Lilly to Adjust Organization and Leadership Structure to Better Align with Growth Opportunities (PR Newswire)
04.01.17	U.S. FDA approves supplemental New Drug Applications to include landmark data in product labels for Synjardy® (empagliflozin/metformin hydrochloride), Synjardy® XR (empagliflozin/metformin... (PR Newswire)
03.01.17	Elanco Animal Health Completes Acquisition of Boehringer Ingelheim Vetmedica's U.S. Feline, Canine and Rabies Vaccines Portfolio (PR Newswire)
29.12.16	Biotech Stocks Facing FDA Decision In January (RTTNews)
28.12.16	US-Behörde zwingt Boehringer zu Zugeständnissen bei Sanofi-Deal (AWP)
28.12.16	US-Behörde zwingt Boehringer zu Zugeständnissen bei Sanofi-Deal (dpa-afx)
20.12.16	Drug Makers Stocks under Scanner -- Bristol-Myers Squibb, AstraZeneca, Eli Lilly, and GlaxoSmithKline (PR Newswire)
19.12.16	Pricewatch Alert: Adobe Systems, Gulfport Energy, Eli Lilly, Coca-Cola, and Visa and more offer option-trading opportunities that offer returns of more than 20% (PR Newswire)
17.12.16	HINTERGRUND: Alzheimer-Forscher geben nach Rückschlag nicht auf (dpa-afx)
16.12.16	CHMP Recommends Approval Of Lilly's Baricitinib For Rheumatoid Arthritis (RTTNews)
16.12.16	CHMP Recommends Approval of Lilly's Baricitinib for the Treatment of Adults with Moderate to Severe Active Rheumatoid Arthritis (RA) (PR Newswire)
15.12.16	MÄRKTE USA/Finanzwerte sorgen für leichten Anstieg der Wall Street (Dow Jones)
15.12.16	MÄRKTE USA/Börsen starten gut behauptet (Dow Jones)
15.12.16	Eli Lilly kappt Gewinnprognose für 2016 - Bessere Aussichten für nächstes Jahr (AWP)
15.12.16	Eli Lilly kappt Gewinnprognose für 2016 - Bessere Aussichten für nächstes Jahr (dpa-afx)
15.12.16	Lilly, Boehringer: Basaglar, A Long-Acting Basal Insulin, Now Available In US (RTTNews)
15.12.16	BASAGLAR® (insulin glargine injection 100 units/mL), A Long-Acting Basal Insulin, Is Now Available in U.S. (PR Newswire)
15.12.16	Lilly Cuts FY16 EPS View, Backs Adj. EPS Forecast; Sees Growth In FY17 (RTTNews)
15.12.16	Lilly Provides 2017 Financial Guidance and 2016 Update, Reaffirms Financial Expectations Through the Remainder of the Decade (PR Newswire)
13.12.16	Lilly Announces Program To Provide Insulin At Discounted Prices Starting Jan. 1 (RTTNews)
13.12.16	Lilly Announces Program to Provide Insulin at Discounted Prices (PR Newswire)
13.12.16	Lilly : FDA Approves Synjardy XR Tablets For Adults With Type 2 Diabetes (RTTNews)
13.12.16	Lilly Announces Dividend Increase (PR Newswire)
12.12.16	U.S. FDA approves Synjardy® XR (empagliflozin/metformin hydrochloride extended-release) tablets for adults with type 2 diabetes (PR Newswire)
09.12.16	Lilly And AstraZeneca In Deal To Co-develop MEDI1814 (RTTNews)
09.12.16	Lilly and AstraZeneca to Develop Second Potentially Disease-Modifying Treatment for Alzheimer's Disease (PR Newswire)
09.12.16	Lilly Reports Detailed Results Of Solanezumab Phase 3 EXPEDITION3 Study (RTTNews)
09.12.16	Lilly Announces Detailed Results of Solanezumab Phase 3 EXPEDITION3 Study at the Clinical Trials on Alzheimer's Disease (CTAD) 2016 Meeting (PR Newswire)
09.12.16	Lilly Announces Detailed Results of Solanezumab Phase 3 EXPEDITION3 Study at the Clinical Trials on Alzheimer's Disease (CTAD) 2016 Meeting (PR Newswire)
08.12.16	Lilly Presents NeoMONARCH Phase2 Data On Abemaciclib In EarlyStage Breast Cancer (RTTNews)
08.12.16	Lilly Presents neoMONARCH Phase 2 Data on Abemaciclib in Early-Stage Breast Cancer (PR Newswire)
05.12.16	FDA Approves Jardiance Tablets To Reduce Cardiovascular Death Risk In Diabetes (RTTNews)
05.12.16	FDA Approves Jardiance Tablets To Reduce Cardiovascular Death Risk In Diabetes (RTTNews)
05.12.16	U.S. FDA approves Jardiance® (empagliflozin) tablets to reduce the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Sonova Hldg	295.60	0.96 %	K V
Lonza Grp	531.00	0.53 %	K V
Alcon	76.02	0.34 %	K V
Roche Hldg G	247.40	0.28 %	K V
ABB	48.86	0.27 %	K V
Swisscom	498.40	-0.62 %	K V
UBS Group	26.71	-0.67 %	K V
Zurich Insur Gr	533.00	-0.97 %	K V
Holcim	86.10	-1.01 %	K V
Sika	213.20	-2.47 %	K V

mehr

20.12.24		Freundlicher Handel in New York: Dow Jones beendet die Sitzung weit in der Gewinnzone
20.12.24		Handel in New York: Am Freitagnachmittag Gewinne im Dow Jones
20.12.24		Dow Jones aktuell: Dow Jones notiert am Mittag im Plus
20.12.24		Verluste in Europa: Euro STOXX 50 letztendlich leichter
20.12.24		Schwacher Handel: SMI schliesst mit Verlusten
20.12.24		Schwache Performance in New York: S&P 500 notiert zum Handelsstart im Minus
20.12.24		Handel in Zürich: SMI verbucht Verluste
20.12.24		Börse Frankfurt: So steht der LUS-DAX am Nachmittag

20.12.24

Freundlicher Handel in New York: Dow Jones beendet die Sitzung weit in der Gewinnzone

20.12.24

Handel in New York: Am Freitagnachmittag Gewinne im Dow Jones

20.12.24

Dow Jones aktuell: Dow Jones notiert am Mittag im Plus

20.12.24

Verluste in Europa: Euro STOXX 50 letztendlich leichter

20.12.24

Schwacher Handel: SMI schliesst mit Verlusten

20.12.24

Schwache Performance in New York: S&P 500 notiert zum Handelsstart im Minus